TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Seres (MCRB) Q3 2025 Earnings Call Transcript

The Motley Fool Logo The Motley Fool • •By Motley Fool Transcribing
Seres (MCRB) Q3 2025 Earnings Call Transcript

Seres Therapeutics reported Q3 2025 earnings, highlighting progress on SER-155, a live biotherapeutic targeting bloodstream infections in stem cell transplant patients. The company secured a $3.6M CARB-X grant, reduced workforce by 25%, and is seeking additional capital to advance clinical trials.

Insights
GOOG   positive

Demonstrated technological leadership by achieving a breakthrough with its Willow quantum chip, running a verifiable algorithm beyond traditional supercomputer capabilities.


MCRB   neutral

Mixed financial performance with net income from a one-time sale offset by ongoing operational losses, ongoing capital constraints, and workforce reduction, but promising clinical trial progress and external grant funding